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Gyneco-Obstetricians
Laboratory
microbiologistPediatricians
Labor/delivery Ward
Intrapartum antimicrobial prophylaxis-IAP
Universal prenatal screening at 35-
37 weeks gestation
Risk-based approach reserved for women with unknown
GBS status at time of labor.
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Why IAP ?
Why a Screening-based approach ?
 Risks for GBS EOD
 Goals of IAP
 Effectiveness
 Belgian choice
 Concerns about use of prophylaxis
 Concerns about number of
candidates for IAP
 Cost-effective analysis
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GBS VERTICAL TRANSMISSION
GBS colonized mothers
Non-colonized
newborns
Colonized
newborns
40 - 60 %
2 - 4 %
GBS EOD
60 - 40 %
96 - 98 %
Asymptomatic
sepsis
pneumonia
meningitis
long term
sequelae CDC
Risk 
factors
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GBS maternal colonization
Risk factor for early-onset disease
(EOD):
vaginal GBS colonization at delivery
 GBS carriers 
 10 - 30 % of women
 Clinical signs not predictive
 Dynamic condition
 Prenatal cultures late in pregnancy can predict
delivery status
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Additional Risk Factors 
for Early-Onset GBS Disease
Obstetric factors: 
 Prolonged rupture of membranes, 
 Preterm delivery, 
 Intrapartum fever
GBS bacteriuria
Previous infant with GBS disease
Immunologic: 
 Low specific IgG to GBS capsular 
polysaccharide
No difference in occurrence either in GBS 
Positive or Negative women, except 
intrapartum fever
Lorquet S., Melin P. & al. 
J Gynecol Obstet Biol Reprod 2005
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GBS EOD - Belgian data
 Incidence
 1985: 3/1000 live births
 1990: 3 cases + 4 likely cases/1000 live births 
 1999, estimation : 2/1000 live births 
 Meningitis : 10 %
 Mortality > 14 %
 60 % EOD (130 cases) : WITHOUT any 
maternal/obstetric risk factor
 Prenatal screening
 Recto-vaginal cultures : 13-25 % GBS Positive
P. Melin, 2001 - Reference laboratory for GBS.
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Prevention of perinatal GBS EOD
 Intrapartum antibiotics
 Highly effective at preventing EOD in women at risk
of transmitting GBS to their newborns ( > 4 h)
INTRAPARTUM ANTIMICROBIAL 
PROPHYLAXIS (IAP) 
 Main goal : 
 To prevent 70 to 80 % of GBS EO cases
 Secondary :
 To reduce peripartum maternal morbidity
pm-ULg GGOLFB.2006 10
How best to 
identify women 
at risk ?
CDC 1996 recommendations
« IAP »
35-37 wks Screening-based strategy
Or 
Risk factors-based strategy
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Screening for GBS 
or risk-factors ?
P.Melin, 40th ICAAC, 2000
L.Mahieu, 2000, J Obst Gyn;5:460-4
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Effectiveness of  both CDC 1996 
approaches
Schrag S. et al. N Engl J Med 2002; 347:233-9
“RF” easier and cheaper than “screening” BUT
 Population-based surveillance study, U.S. 
 312 GBS EOD ; > 600 000 live births 
 AUDIT (5144 files): « IAP given when mandatory »
 52 % of all deliveries had screening
 IAP given more often if « GBS Positive screening »
than if presence of >= 1 RF
“Screening” > 50 % more effective than “RF”
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Why is Screening more protective
than the risk-based approach ?
Broader coverage of « at-risk »
population
 Captures colonized women without
obstetric RF
 High level of compliance with
recommendations
 Enhanced compliance with risk-based
approach cannot prevent as many cases 
as universal screening
pm-ULg GGOLFB.2006 15
CDC
The Recommendations
MMWR, Vol 51
(RR-11) August 2002
Universal prenatal 
screening
& RF reserved for 
unknown GBS culture 
results 
Endorsed by AAP 
and by ACOG
in 2002
pm-ULg GGOLFB.2006 16
Screening-based strategy for prevention
of GBS perinatal disease (Belgian CH, 2003)
Recto-vaginal GBS screening culture  at 35-37 weeks of gestation 
For ALL pregnant women
Recto-vaginal GBS screening culture  at 35-37 weeks of gestation 
For ALL pregnant women
> 1 Risk factor: 
- Intrapartum fever > 38°C***
- ROM > 18 hrs
> 1 Risk factor: 
- Intrapartum fever > 38°C***
- ROM > 18 hrs
Intrapartum prophylaxis NOT indicated
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Neg Pos
if NO if YES
Unless patient had a previous infant with GBS invasive disease
or GBS bacteriuria during current pregnacy
or delivery occurs < 37 weeks’ gestation *
GBS Neg
if  YES
GBS POSNot done, incomplete
or unknown GBS result
! Facultative ! 
Intrapartum rapid GBS Ag test**
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Prenatal GBS screening : 
Laboratory procedure (Belgian CH, 2003)
35-37 wks V+R
Selective enrichment broth (eg.LIM)
Overnight, 35-37°C
Sub-culture onto “Granada” agar
Overnight, 35-37°C anaerobically
POSITIVE screening Negative screening
Presence 
of orange
colonies
= GBS 
Absence of 
orange 
colonies 
Minimum:
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What to do in case of Positive 
GBS screening ?
 Send results to requesting doctor and
a copy to expected site for delivery
 DO NOT treat during pregnancy if 
asymptomatic
 ( ! To treat if GBS bacteriuria ! )
 To schedule IAP
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Feasibility in Belgium
 Screening
 Follow-up visit already scheduled around
35-37 wks gestation
 Accessability to laboratories
 IAP (intra-venous)
 Most of deliveries occur at hospital
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Concerns about potential
adverse / unintended
consequences of prophylaxis
 Allergies 
 Anaphylaxis occurs but rarely
 Changes in incidence or resistance of other
pathogens causing EOD
 Data are complex …
 BUT Most studies: stable rates of « other »
sepsis
 Changes in GBS antimicrobial resistance
profile
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Concerns about potential
adverse / unintended
consequences of prophylaxis
 Management of neonates
 Increase of unecessary evaluation
 Increase of unecessary antimicrobial
treatments
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Management of neonates at
risk for GBS EOD
Rem.: 95 % of GBS EOD are symptomatic < 24 h of live
Neonates born to women who received IAP
Symptomatic NN / asymptomatic NN
At low/at high risk .
To minimize unnecessary evaluation and
antimicrobial treatment
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Concerns about the number of 
women who are given IAP
Prevalence of factors inducing the decision of IAP 
(CHR Liege, 2002, 1350 consecutive deliveries)
/
19 %
1.6 %
15-25 %
/
/
GBS Positive
ROM >= 18 h
T° >= 38°C
17 %
1.2 %
Prematurity
GBS bacteriuria
« RISK FACTORS »
OPTION
« SREENING »
OPTION
FACTORS
Lorquet, Melin, Foidart, J Gynecol Obstet Biol Reprod 2005 
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Perinatal GBS disease burden
 Neonatal illness / death, 
 Long-term disability
 Maternal morbidity
Neonatal direct costs plus indirect costs.
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+/- 250
<< 50 %
166
/
N € x 166
+/- 3,300 €
not estimated*
+/- 250
75 %
111
2,200 €
N € x 111
+/- 3,300 €
not estimated*
Patients treated/1000 births
GBS cases prevented (%)
Patients treated/prevented
case
Lab cost /prevented case
IAP cost /prevented case
Min.cost /case (8 d, ICU/NN)
Indirect cost, sequelae, etc
PRM >= 18 h, 
T°>=38°C
GBS +Criteria for IAP
RF optionsScreening option
Hypothesis: GBS prevalence in women: 20% ; Natural incidence of GBS EOD: 3/1000 ; 
prevalence of RF as in our study in Liege in 2002
* If additional cost/case > 4500 €, Screening is cost effective versus RF
Rough cost-effective « analysis »
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Conclusions & perspectives
Prevention of GBS perinatal Diseases
PRO-SCREENING
Currently the best choice but NOT the ideal
strategy
Temporary, waiting for vaccines, other approach
 To implement in the daily practice
 V+R Screening method
 !! Transmission of results !!
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Key GBS Resources
 MMWR : August 16, 2002 / 51(RR11); 1-22
 ACOG Comm Opin 2002, N°279
 Obstet Gynecol, 2002;100:1405-12
 CDC ’s GBS Internet page
 http://www.cdc.gov/groupBstrep/
 Conseil supérieur d’hygiène (brochure strep B)
 http://www.health.fgov.be/CSH_HGR
